Combination therapy with AAGL and anti-PD-1 further prolonged the lifespan and resulted in cell numbers of T cells and macrophages in the livers of H22 tumor-bearing mice exceeding those observed after AAGL or anti-PD-1 therapy alone. Here, PDCD1 is linked to neoplasm.